DGAP-News: Apricus Biosciences Presents Vitaros(R) Poster at the International Symposium on Prostate, Androgens and Men's Sexual Health

| Source: EQS Group AG
Apricus Biosciences, Inc. 

21.06.2013 09:00

Data Demonstrate Increased Efficacy, Decreased Adverse Events, With Longer Term

SAN DIEGO, 2013-06-21 09:00 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(www.apricusbio.com) announced today that it will present a poster with results
of an analysis of existing Phase 3 data for Vitaros(r), the Company's lead
product candidate for the treatment of erectile dysfunction (ED), at the
International Symposium on Prostate, Androgens and Men's Sexual Health. The
Symposium is being convened jointly by the European Society of Sexual Medicine
('ESSM') and the International Society for Sexual Medicine ('ISSM'), and is
taking place June 21-23, 2013 in Berlin, Germany. 

The poster, titled 'Comparison of Vitaros(r) Efficacy and Safety with Short-term
and Longer Term Use,' (Poster #35) authored by John P. Mulhall, M.D., Director
of the Male Sexual and Reproductive Medicine Program at Memorial
Sloan-Kettering Cancer Center, is scheduled to be on display June 21-22, 2013
from 9:00 AM to 5:00 PM local time. 

'Vitaros(r) addresses a large population of ED patients who cannot or do not
respond well to existing medications due to the systemic effects of PDE5
inhibitors, such as Viagra,' said Rich Pascoe, Chief Executive Officer of
Apricus Bio. 'With its innovative, on-demand topical administration, and rapid
onset in as little as five minutes, Vitaros(r) can safely improve erectile
function in these patients with both short and longer term use.' 

This additional analysis of the Phase 3 data looked at the efficacy and safety
of Vitaros(r) for short-term use (12 weeks; n=1,727) compared to longer-term use
(n=1,161). The results found that, following 12 weeks of treatment, a
statistically significant improvement in erectile function (EF) score was
observed for the Vitaros(r) treatment group (1.6 for the 100 mcg dose group, 2.5
for the 200 mcg dose group, and 2.4 for the 300 mcg dose group) compared to the
placebo group (-0.7) (p<0.001). A significantly greater proportion of patients
receiving all dose levels of Vitaros(r) (100 mcg, 200 mcg, 300 mcg) reported
improvement (up to 51%) in their erections compared to placebo. 

With longer-term exposure, nearly all of the subjects (100%, 100%, and 88.2% in
each of the 100mcg, 200mcg, and 300mcg dose groups respectively) had an
improvement in EF score, and greater than 90% of the patients reported
improvements in their erections. Compared to the end of the 12-week treatment,
the mean IIEF score continued to improve for men choosing the 300 mcg dose
level. The increased efficacy and the longer term safety evaluated in ED
patients repeatedly exposed to Vitaros(r) illustrated that efficacy does not
diminish with longer term use. 

The majority of adverse events (AEs) were transient, and mild or moderate in
intensity, and the incidence of AE reports decreased with repeated exposure.
Relative to 12-week Vitaros(r) administration, longer term use of Vitaros(r)
resulted in consistent, dose-dependent overall improvement in EF and fewer
reports of transient urogenital adverse events. 

The Company received approval effective May 31, 2013 of Vitaros(r) in Europe as
first line treatment for erectile dysfunction. The Company is currently working
independently, as well as with its commercialization partners, Sandoz, Takeda,
and Bracco, to obtain national phase approvals in France, Germany, Italy, UK,
Ireland, Spain, The Netherlands, Sweden, Belgium and Luxembourg in order to
make Vitaros(r) ready to launch in each of these territories across Europe.
Vitaros(r) is also approved in Canada. 

About Vitaros(r)

Vitaros(r) is a topically-applied cream formulation of alprostadil, a
vasodilator, combined with our proprietary permeation enhancer DDAIP.HCL, which
directly increases blood flow to the penis, causing an erection. Alprostadil is
a widely accepted alternative to the PDE-5 inhibitors for difficult to treat
patients, and Vitaros(r), which was determined to be safe and effective by the
European Health Authorities and previously by Health Canada, offers greater
market opportunity due to its patient-friendly form versus other alprostadil
dosage forms and also relative to oral ED products. With a market affecting
nearly 150 million men worldwide and representing approximately $1 billion in
revenue in Europe, Vitaros(r) represents a major market opportunity,
as a distinct product that addresses a significant underserved population. 

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros(r), for the treatment of
erectile dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus Bio's marketing partners which include, Abbott
Canada, Takeda Pharmaceuticals International GmbH, Sandoz, and Bracco SpA.
Femprox(r), the Company's product candidate for the treatment of female sexual
arousal disorder, has successfully completed a nearly 400-subject
proof-of-concept study. 

For further information on Apricus Bio, visit http://www.apricusbio.com.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its product
Vitaros(r) for erectile dysfunction , and product candidate Femprox(r) for
Sexual Arousal Disorder among others; to have its product and product
candidates receive additional patent protection and be approved by relevant
regulatory authorities in Europe, the United States and Canada and in other
countries; to successfully commercialize such product and product candidates
and other NexACT(r) product candidates and drug delivery technology; to sell its
oncology supportive care business or assets to a third party or parties; to
cease funding to its French subsidiaries and to have such subsidiaries
reorganize or liquidate successfully; and to achieve its other development,
commercialization and financial goals. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers are
urged to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company. 

         CONTACT: Apricus Bio Investor Relations:
         David Pitts or Lourdes Catala
         Argot Partners
News Source: NASDAQ OMX

21.06.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:     English
Company:      Apricus Biosciences, Inc.
              United States
ISIN:         US9901429525
End of Announcement                             DGAP News-Service